Latent Toxoplasma gondii infection leads to improved action control

Brain, Behavior, and Immunity

Volumn 37, Issue , 2014, Pages 103-108

  Stock, Ann Kathrin ^a   Heintschel von Heinegg, Evelyn ^b   Köhling, Hedda Luise ^b   Beste, Christian ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Action cascading; Dopamine; EEG; Executive functions; Human; Latent toxoplasmosis; Manipulation hypothesis; Parasite; Stop change paradigm; Toxoplama gondii

Indexed keywords

DOPAMINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY;

ADULT; ARTICLE; BEHAVIOR CONTROL; DOPAMINERGIC TRANSMISSION; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAM; EXECUTIVE FUNCTION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NEUROMODULATION; NEUROPHYSIOLOGY; NORMAL HUMAN; PRIORITY JOURNAL; RESPONSE TIME; TOXOPLASMA GONDII; TOXOPLASMOSIS; YOUNG ADULT;

ACTION CASCADING; DOPAMINE; EEG; EXECUTIVE FUNCTIONS; HUMAN; LATENT TOXOPLASMOSIS; MANIPULATION HYPOTHESIS; PARASITE; STOP-CHANGE PARADIGM; TOXOPLAMA GONDII;

ADULT; BRAIN; COGNITION; ELECTROENCEPHALOGRAPHY; EXECUTIVE FUNCTION; FEMALE; HUMANS; INHIBITION (PSYCHOLOGY); MALE; TOXOPLASMOSIS; YOUNG ADULT;

EID: 84896730545     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2013.11.004     Document Type: Article

References (58)

1. Aarts E., Roelofs A., Franke B., Rijpkema M., Fernández G., Helmich R.C., Cools R. Striatal dopamine mediates the interface between motivational and cognitive control in humans: evidence from genetic imaging. Neuropsychopharmacology 2010, 35:1943-1951.
2. Alonso R., Chaudieu I., Diorio J., Krishnamurthy A., Quirion R., Boksa P. Interleukin-2 modulates evoked release of [3H]dopamine in rat cultured mesencephalic cells. J. Neurochem. 1993, 61:1284-1290.
3. Avila C., Garbin G., Sanjuán A., Forn C., Barrós-Loscertales A., Bustamante J.C., Rodríguez-Pujadas A., Belloch V., Parcet M.A. Frontostriatal response to set switching is moderated by reward sensitivity. Soc. Cogn. Affect. Neurosci. 2012, 7:423-430.
4. Barnes J.J.M., Dean A.J., Nandam L.S., O'Connell R.G., Bellgrove M.A. The molecular genetics of executive function: role of monoamine system genes. Biol. Psychiatry 2011, 69:e127-143.
5. Berdoy M., Webster J.P., Macdonald D.W. Fatal attraction in rats infected with Toxoplasma gondii. Proc. Biol. Sci. 2000, 267:1591-1594.
6. Beste C., Saft C., Konrad C., Andrich J., Habbel A., Schepers I., Jansen A., Pfleiderer B., Falkenstein M. Levels of error processing in Huntington's disease: a combined study using event-related potentials and voxel-based morphometry. Hum. Brain Mapp. 2008, 29:121-130.
7. Beste C., Willemssen R., Saft C., Falkenstein M. Error processing in normal aging and in basal ganglia disorders. Neuroscience 2009, 159:143-149.
8. Beste C., Baune B.T., Domschke K., Falkenstein M., Konrad C. Dissociable influences of NR2B-receptor related neural transmission on functions of distinct associative basal ganglia circuits. Neuroimage 2010, 52:309-315.
9. Beste C., Kolev V., Yordanova J., Domschke K., Falkenstein M., Baune B.T., Konrad C. The role of the BDNF Val66Met polymorphism for the synchronization of error-specific neural networks. J. Neurosci. 2010, 30:10727-10733.
10. Boothroyd J.C., Grigg M.E. Population biology of Toxoplasma gondii and its relevance to human infection: do different strains cause different disease?. Curr. Opin. Microbiol. 2002, 5:438-442.
11. Chambers C.D., Garavan H., Bellgrove M.A. Insights into the neural basis of response inhibition from cognitive and clinical neuroscience. Neurosci. Biobehav. Rev. 2009, 33:631-646.
12. Cools R., Barker R.A., Sahakian B.J., Robbins T.W. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb. Cortex 2001, 11:1136-1143.
13. Di Russo F., Martínez A., Hillyard S.A. Source analysis of event-related cortical activity during visuo-spatial attention. Cereb. Cortex 2003, 13:486-499.
14. Eagle D.M., Baunez C. Is there an inhibitory-response-control system in the rat? evidence from anatomical and pharmacological studies of behavioral inhibition. Neurosci. Biobehav. Rev. 2010, 34:50-72.
15. Falkenstein M., Hohnsbein J., Hoormann J. Effects of choice complexity on different subcomponents of the late positive complex of the event-related potential. Electroencephalogr. Clin. Neurophysiol. 1994, 92:148-160.
16. Falkenstein Michael., Hohnsbein J., Hoormann J. Time pressure effect on late components of the event-related potential (ERP). J. Psychophysiol. 1994, 8:22-30.
17. Flegr J. How and why Toxoplasma makes us crazy. Trends Parasitol. 2013, 29:156-163.
18. Garcia-Garcia M., Barceló F., Clemente I.C., Escera C. The role of the dopamine transporter DAT1 genotype on the neural correlates of cognitive flexibility. Eur. J. Neurosci. 2010, 31:754-760.
19. Gaskell E.A., Smith J.E., Pinney J.W., Westhead D.R., McConkey G.A. A unique dual activity amino acid hydroxylase in Toxoplasma gondii. PLoS ONE 2009, 4:e4801.
20. Goldman-Rakic P.S., Muly E.C., Williams G.V. D(1) receptors in prefrontal cells and circuits. Brain Res. Brain Res. Rev. 2000, 31:295-301.
21. Halonen S.K., Lyman W.D., Chiu F.C. Growth and development of Toxoplasma gondii in human neurons and astrocytes. J. Neuropathol. Exp. Neurol. 1996, 55:1150-1156.
22. Henriquez S.A., Brett R., Alexander J., Pratt J., Roberts C.W. Neuropsychiatric disease and Toxoplasma gondii infection. NeuroImmunoModulation 2009, 16:122-133.
23. Herrmann C.S., Knight R.T. Mechanisms of human attention: event-related potentials and oscillations. Neurosci. Biobehav. Rev. 2001, 25:465-476.
24. Humphries M.D., Stewart R.D., Gurney K.N. A physiologically plausible model of action selection and oscillatory activity in the basal ganglia. J. Neurosci. 2006, 26:12921-12942.
25. Jones-Brando L., Torrey E.F., Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr. Res. 2003, 62:237-244.
26. Kamerkar S., Davis P.H. Toxoplasma on the brain: understanding host-pathogen interactions in chronic CNS infection. J. Parasitol. Res. 2012, 2012:589295.
27. Kok A., Ramautar J.R., De Ruiter M.B., Band G.P.H., Ridderinkhof K.R. ERP components associated with successful and unsuccessful stopping in a stop-signal task. Psychophysiology 2004, 41:9-20.
28. Logan G.D., Cowan W.B. On the ability to inhibit thought and action: a theory of an act of control. Psychol. Rev. 1984, 91:295-327.
29. Martínez A., Teder-Sälejärvi W., Vazquez M., Molholm S., Foxe J.J., Javitt D.C., Di Russo F., Worden M.S., Hillyard S.A. Objects are highlighted by spatial attention. J. Cogn. Neurosci. 2006, 18:298-310.
30. McConkey G.A., Martin H.L., Bristow G.C., Webster J.P. Toxoplasma gondii infection and behaviour - location, location, location?. J. Exp. Biol. 2013, 216:113-119.
31. Moore J. Altered behavioural responses in intermediate hosts - an acanthoceptalan parasite strategy. Am. Nat. 1984, 123:572-577.
32. Mückschel M., Stock A.-K., Beste C. Psychophysiological mechanisms of interindividual differences in goal activation modes during action cascading. Cereb. Cortex. 2013, [Epub ahead of print]. 10.1093/cercor/bht066.
33. O'Connell R.G., Dockree P.M., Bellgrove M.A., Turin A., Ward S., Foxe J.J., Robertson I.H. Two types of action error: electrophysiological evidence for separable inhibitory and sustained attention neural mechanisms producing error on go/no-go tasks. J. Cogn. Neurosci. 2009, 21:93-104.
34. Oldfield R.C. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971, 9:97-113.
35. Petitto J.M., McCarthy D.B., Rinker C.M., Huang Z., Getty T. Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2. J. Neuroimmunol. 1997, 73:183-190.
36. Polich J. Updating P300: an integrative theory of P3a and P3b. Clin. Neurophysiol. 2007, 118:2128-2148.
37. Prandovszky E., Gaskell E., Martin H., Dubey J.P., Webster J.P., McConkey G.A. The neurotropic parasite Toxoplasma gondii increases dopamine metabolism. PLoS ONE 2011, 6:e23866.
38. Ratsma J.E., van der Stelt O., Schoffelmeer A.N., Westerveld And A., Boudewijn Gunning W. P3 event-related potential, dopamine D2 receptor A1 allele, and sensation-seeking in adult children of alcoholics. Alcohol. Clin. Exp. Res. 2001, 25:960-967.
39. Ravizza S.M., Goudreau J., Delgado M.R., Ruiz S. Executive function in Parkinson's disease: contributions of the dorsal frontostriatal pathways to action and motivation. Cogn. Affect. Behav. Neurosci. 2012, 12:193-206.
40. Redgrave P., Prescott T.J., Gurney K. The basal ganglia: a vertebrate solution to the selection problem?. Neuroscience 1999, 89:1009-1023.
41. Robbins T.W., Arnsten A.F.T. The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu. Rev. Neurosci. 2009, 32:267-287.
42. Robert-Gangneux F., Dardé M.-L. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin. Microbiol. Rev. 2012, 25:264-296.
43. Schulz S., Arning L., Pinnow M., Wascher E., Epplen J.T., Beste C. When control fails: influence of the prefrontal but not striatal dopaminergic system on behavioural flexibility in a change detection task. Neuropharmacology 2012, 62:1028-1033.
44. Seamans J.K., Yang C.R. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog. Neurobiol. 2004, 74:1-58.
45. Skallová A., Kodym P., Frynta D., Flegr J. The role of dopamine in Toxoplasma-induced behavioural alterations in mice: an ethological and ethopharmacological study. Parasitology 2006, 133:525-535.
46. Stock A.-K., Blaszkewicz M., Beste C. Effects of binge drinking on action cascading processes: an EEG study. Arch. Toxicol. 2013, [Epub ahead of print]. 10.1007/s00204-013-1109-2.
47. Tenter A.M., Heckeroth A.R., Weiss L.M. Toxoplasma gondii: from animals to humans. Int. J. Parasitol. 2000, 30:1217-1258.
48. Treuer T., Martenyi F., Karagianis J. Parasitosis, dopaminergic modulation and metabolic disturbances in schizophrenia: evolution of a hypothesis. Neuro Endocrinol. Lett. 2007, 28:535-540.
49. Van Holstein M., Aarts E., van der Schaaf M.E., Geurts D.E.M., Verkes R.J., Franke B., van Schouwenburg M.R., Cools R. Human cognitive flexibility depends on dopamine D2 receptor signaling. Psychopharmacology 2011, 218:567-578.
50. Verbruggen F., Schneider D.W., Logan G.D. How to stop and change a response: the role of goal activation in multitasking. J. Exp. Psychol. Hum. Percept. Perform. 2008, 34:1212-1228.
51. Verleger R. The true P3 is hard to see: some comments on Kok's (1986) paper on degraded stimuli. Biol. Psychol. 1988, 27:45-50.
52. Verleger R., Jaśkowski P., Wascher E. Evidence for an integrative role of P3b in linking reaction to perception. J. Psychophysiol. 2005, 19:165-181.
53. Vyas A., Kim S.-K., Giacomini N., Boothroyd J.C., Sapolsky R.M. Behavioral changes induced by Toxoplasma infection of rodents are highly specific to aversion of cat odors. Proc. Natl. Acad. Sci. USA 2007, 104:6442-6447.
54. Webster J.P. Rats, cats, people and parasites: the impact of latent toxoplasmosis on behaviour. Microbes Infect. Inst. Pasteur 2001, 3:1037-1045.
55. Webster J.P. The effect of Toxoplasma gondii on animal behavior: playing cat and mouse. Schizophr. Bull. 2007, 33:752-756.
56. Webster J.P., Kaushik M., Bristow G.C., McConkey G.A. Toxoplasma gondii infection, from predation to schizophrenia: can animal behaviour help us understand human behaviour?. J. Exp. Biol. 2013, 216:99-112.
57. Webster J.P., Lamberton P.H.L., Donnelly C.A., Torrey E.F. Parasites as causative agents of human affective disorders? the impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii's ability to alter host behaviour. Proc. Biol. Sci. 2006, 273:1023-1030.
58. Willemssen R., Müller T., Schwarz M., Falkenstein M., Beste C. Response monitoring in de novo patients with Parkinson's disease. PLoS ONE 2009, 4:e4898.